Clinical Trials Browser

Phase 1/2 × Completed × lazertinib × Clear all

NCT04075396 2025-04-29

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

29 enrolled 53 charts

Carcinoma, Non-Small-Cell Lung